




# AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A process for the preparation of tetrahydrothieno[3,2-c]pyridine compound derivatives of the general formula 6:




or their pharmaceutically acceptable salts, wherein the meaning of X is carboxyl, alkoxycarbonyl, aryloxy, or carbamoyl of formula



wherein R<sub>1</sub> and R<sub>2</sub> can be individually or simultaneously hydrogen, alkyl or part of a heterocyclic structure; Z can be hydrogen, halogen, alkyl, aryl, aryloxy or alkoxy group, the process comprising conducting a dehydroxylation reaction on the compound of formula 5 in order to obtain a compound of formula 6, wherein said dehydroxylation reaction is effected by iodosilane represented by the formula

$\text{Si}(\text{R}_3)_3\text{I}$ , wherein  $\text{R}_3$  selected from an alkyl, alkenyl, alkynyl, aromatic group, or combinations of thereof.



2. (original) The process of Claim 1 wherein said iodosilane is iodotrimethylsilane (TMSI).

3. (original) The process of Claim 1 or 2 wherein said iodosilane is generated *in situ* in the reaction between chlorosilanes of formula  $\text{Si}(\text{R}_4)_3\text{Cl}$  and sodium iodide, wherein  $\text{R}_4$  is selected from an alkyl, alkenyl, alkynyl, or aromatic group, or combinations of thereof.

4. (original) The process of Claim 3 wherein said chlorosilanes is chlorotrimethylsilane.

5. (original) The process of Claim 1 wherein the compound of formula 6 is racemic or enantiomerically enriched Clopidogrel or pharmaceutical salts thereof.

6. (original) The process of Claim 1 or 2 wherein the compound of formula 5 is in a free base form or in a salt form.


7. (original) The process of Claim 1 wherein the reaction is conducted under a polar

aprotic solvent, an aromatic solvent , or mixtures thereof.

8. (original) The process of Claim 7 wherein the polar aprotic solvent is selected from acetonitrile,  $\text{CH}_2\text{Cl}_2$ , *N, N'*-dimethylformamide and combinations thereof.

9. (original) The process of Claim 7 wherein the aromatic solvent is selected from toluene and equivalent thereof.

10. (currently amended) A process for the preparation of compound of formula **1** or its pharmaceutically acceptable salts thereof, comprising conducting a dehydroxylation reaction on the compound of formula **9** or its salts thereof, wherein said dehydroxylation reaction is effected by iodotrimethylsilane (TMSI)[[.]]



11. (original) The process of Claim 10 wherein the reaction is conducted under a polar aprotic solvent, an aromatic solvent , or mixtures thereof.

12. (original) The process of Claim 11 wherein the polar aprotic solvent is selected from acetonitrile,  $\text{CH}_2\text{Cl}_2$ , *N, N'*-dimethylformamide and combinations thereof.

13. (original) The process of Claim 11 wherein the aromatic solvent is selected from toluene and equivalent thereof.